ClinicalTrials.gg
Active, not recruitingNCT05245006Updated Mar 17, 2026

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

A Phase 1 interventional study of 89Zr-DFO-YS5 and YS5 antibody in Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, sponsored by Robert Flavell, MD, PhD. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Robert Flavell, MD, PhD · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
1,897th of 3,024
30 · median 48
Started
2022
with 120 others
Phase 1
615 of 3,597
81 open now
Primary completion
2027-07
later than 439 of 968 live
Registered
2,839th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 1,897th largest by enrollment of the 3,024 interventional ones that give a count, is one of 121 that started in 2022, is one of 615 in phase 1, reaches primary completion later than 439 of the 968 other live ones, and was the 2,839th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRPC, and particularly common in the most lethal forms of the disease including adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC). These data will provide crucial information about the feasibility of targeting cluster of differentiation 46 (CD46) in mCRPC, will be used guide the development of novel therapeutic and theranostic agents, to help develop treatments that improve outcomes for men with the most lethal forms of prostate cancer.

Read the detailed description

This single center imaging study involves one microdose of the imaging agent, followed by whole body PET imaging. Imaging data will be acquired in up to four PET studies to determine tumor and normal tissue uptake and dosimetry.

PRIMARY OBJECTIVES:

  1. To determine the optimal time point for imaging (based on analyzing the 4 scans of all participants using 89Zr-DFO-YS5 PET post-injection). (Cohort A)
  2. To determine the optimal antibody dose for imaging using 89Zr-DFO-YS5 PET. (Cohort B).
  3. To determine the sensitivity of metastatic lesion detection in mCRPC using 89Zr-DFO-YS5 PET as compared with conventional imaging (Cohorts C)

SECONDARY OBJECTIVES:

  1. To determine the safety of 89Zr-DFO-YS5.
  2. To determine average organ uptake of 89Zr-DFO-YS5 (Cohort C).
  3. To descriptively report the patterns of intra-tumoral uptake of 89Zr-DFO-YS5 on whole body PET, including by site of disease, uptake by tumor type, inter-tumoral and inter-patient heterogeneity, and tumor-to-background signal (Cohorts C).

OUTLINE: Participants were originally assigned to 1 of 3 cohorts. Cohort B is closed to accrual. Enrollment into Cohort A and C are ongoing.

Cohort A: PET imaging data will be acquired up to four times to determine tumor and normal tissue uptake and dosimetry. The optimized scan time will be used for imaging in Cohorts B and C.

(CLOSED) Cohort B: A dose of cold, non-radiolabeled antibody administered will be varied to determine the optimal antibody dose for image quality. The optimized antibody dose will be used in Cohort C. Participants will be followed for an additional 4-5 weeks after dose administration to assess for adverse events.

Cohort C: PET imaging will be acquired at the optimal time point and optimal antibody dose determined in Cohorts A \& B, and have the option to obtain an repeat scan at the time of disease progression.

All participants will be followed for up to 5 weeks after their first scan to assess for adverse events and will be followed-up until progression. At the time of progression, participants will have the option to receive a repeat scan.

03

Conditions studied

  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • First-in-Human
  • immunoPET agent
  • CD46 positive malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have or cytologically confirmed , castration resistant prostate cancer (mCRPC).
  2. Age >=18 years
  3. (ECOG) performance status \< 2 ( >60%).
  4. Demonstrates adequate organ function as defined below:

    1. Total \<1.5 X (ULN).
    2. (AST)(serum glutamic-oxaloacetic transaminase (SGOT)) \<= 3 X institutional upper limit of normal (ULN).
    3. Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) \<= 3 X institutional ULN.
    4. Serum creatinine \<=1,5 X institutional ULN or calculated ( (GFR)) >= 60 mL/min, calculated using the Cockcroft-Gault equation.
  5. Ability to understand a written document, and the willingness to sign it.
  6. Individuals with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients who because of age, general medical, or psychiatric condition, or physiologic status cannot give valid .
  2. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort A: 89Zr-DFO-YS5

    Participants receive one dose of 89Zr-DFO-YS5 up to 3 millicurie (mCi), and undergo a whole body PET performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total. The optimized scan time will be used for imaging in cohorts B and C. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.

    Drug: 89Zr-DFO-YS5 · Procedure: Positron Emission Tomography (PET)/Computerized tomography (CT) · Procedure: Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)

  • Experimental
    Cohort B: 89Zr-DFO-YS5, YS5 antibody

    Participants receive either a 20mg or 50mg dose of YS5 prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. The optimal dose of unmodified YS5 antibody will be used in the following cohorts C \& D. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.

    Drug: 89Zr-DFO-YS5 · Biological: YS5 antibody · Procedure: Positron Emission Tomography (PET)/Computerized tomography (CT) · Procedure: Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)

  • Experimental
    Cohort C: 89Zr-DFO-YS5, Optimal dose YS5 antibody

    Participants receive optimal dose of YS5 antibody prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.

    Drug: 89Zr-DFO-YS5 · Biological: YS5 antibody · Procedure: Positron Emission Tomography (PET)/Computerized tomography (CT) · Procedure: Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)

Interventions

  • Drug89Zr-DFO-YS5

    3 mCi will be administered intravenously

    Also known as: immunoPET agent, Imaging Agent

  • BiologicalYS5 antibody

    20 or 50 mg administered intravenously

    Also known as: YS5, Unmodified YS5 antibody

  • ProcedurePositron Emission Tomography (PET)/Computerized tomography (CT)

    Imaging which combines a CT scan and a PET scan

    Also known as: PET/CT, PET/CT Scan, Whole Body PET/CT

  • ProcedurePositron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)

    Imaging which combines an MRI scan and a PET scan

    Also known as: PET/CT, PET/MRI Scan, Whole Body PET/MRI

06

What researchers measure

Primary outcomes

  1. Optimal time point for imaging using 89Zr-DFO-YS5 PET post-injection (Cohort A)

    For Cohort A, the optimal time point will be selected based on optimal maximun Standardized uptake value (SUVmax) of metastatic lesions, and ratio of SUVmax to blood pool. Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant.

    Time frame: Up to 7 days

  2. Optimal antibody dose for imaging using 89Zr-DFO-YS5 PET (Cohort B)

    For Cohort B, the optimal dose of antibody will be selected based on the optimal SUVmax of metastatic lesions, and ratio of SUVmax to blood pool. Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant.

    Time frame: Up to 7 days

  3. Proportion of participants with metastatic lesions accurately detected in mCRPC using 89Zr-DFO-YS5 PET (sensitivity) (Cohort C)

    Sensitivity is the probability that a test will indicate disease among those with the actual disease: True Positive / (True Positive + False Negative). Lesions will be graded on a semi-quantitative scale ranging from 1-5 as is common for 89Zr-antibody human imaging studies (1 = no uptake, 2 = probably no uptake, 3 = equivocal, 4 = probably positive, 5 = definitely positive). Using as a cut-off to 4 or 5 on the semi-quantitative scale, the sensitivity of 89Zr-DFO-YS5 PET will be descriptively reported on a lesion-per-lesion basis, using as reference standard staging scans including CT or MRI of the chest/abdomen/pelvis and whole body bone scan. The sensitivity estimate will be based on lesion level without considering the location of the lesions or the possible intra-correlation of the lesions from the same patient.

    Time frame: Up to 24 months

  4. Median SUVmax (Cohort C)

    The median and range of SUVmax across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values will be reported with range of SUVmax.

    Time frame: Up to 24 months

  5. Average SUVmax (SUVmax-ave) (Cohort C)

    The average SUVmax-ave across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values for all cohorts will be reported with 95% confidence intervals

    Time frame: Up to 24 months

Secondary outcomes

  1. Proportion of participants with treatment-related Adverse Events

    The frequency and severity of adverse events following Zr-DFO-YS5 injection will be descriptively reported, using CTCAE version 5.0

    Time frame: Up to 3 weeks after last dose administration, approximately 35 days

  2. Average organ uptake of 89Zr-DFO-YS5 (Cohort C)

    Average organ uptake of 89Zr-DFO-YS5 on PET will be estimated.

    Time frame: Up to 24 months

  3. Intra-tumoral uptake of 89Zr-DFO-YS5 by tumor type (Cohort C)

    The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported

    Time frame: Up to 24 months

  4. Intra-tumoral uptake of 89Zr-DFO-YS5 by Site of Disease (Cohort C)

    The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported

    Time frame: Up to 24 months

  5. Inter-tumoral heterogeneity (Cohort C)

    The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-tumoral heterogeneity.

    Time frame: Up to 24 months

  6. Inter-participant heterogeneity (Cohort C)

    The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-participant heterogeneity

    Time frame: Up to 24 months

  7. Tumor-to-background signal (Cohort C)

    The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported

    Time frame: Up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2027, 64 months after the start.

Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 64 months is above that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 17, 2022
StartActual
Mar 18, 2022
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245006
Lead sponsor
Robert Flavell, MD, PhD
Collaborators
United States Department of Defense, Fortis Therapeutics, Inc.
Responsible party
Robert Flavell, MD, PhD (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Feb 17, 2022
Start date
Mar 18, 2022
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Robert Flavell, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion